The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
Open accessAbstract
Bicyclic nitroimidazoles, including PA-824, are exciting candidates for the treatment of tuberculosis. These prodrugs require intracellular activation for their biological function. We found that Rv3547 is a deazaflavin-dependent nitroreductase (Ddn) that converts PA-824 into three primary metabolites; the major one is the corresponding des-nitroimidazole (des-nitro). When derivatives of PA-824 were used, the amount of des-nitro metabolite formed was highly correlated with anaerobic killing of Mycobacterium tuberculosis (Mtb). Des-nitro metabolite formation generated reactive nitrogen species, including nitric oxide (NO), which are the major effectors of the anaerobic activity of these compounds. Furthermore, NO scavengers protected the bacilli from the lethal effects of the drug. Thus, these compounds may act as intracellular NO donors and could augment a killing mechanism intrinsic to the innate immune system.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics
Lundberg, J. O., Weitzberg, E., & Gladwin, M. T. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2466 · Cited by 2,739
Detection and Imaging of Nitric Oxide with Novel Fluorescent Indicators: Diaminofluoresceins
Kojima, H., Nakatsubo, N., Kikuchi, K., Kawahara, S., Kirino, Y., Nagoshi, H., Hirata, Y., & Nagano, T. (1998) · Analytical Chemistry · doi:10.1021/ac9801723 · Cited by 1,389
Identification of nitric oxide synthase as a protective locus against tuberculosis
MacMicking, J. D., North, R. J., LaCourse, R., Mudgett, J. S., Shah, S. K., & Nathan, C. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5243 · Cited by 1,180
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Self-citationMatsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., & Komatsu, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030466 · Cited by 751
The Transcriptional Responses of Mycobacterium tuberculosis to Inhibitors of Metabolism
Boshoff, H. I. M., Myers, T. G., Copp, B. R., McNeil, M. R., Wilson, M. A., & Barry, C. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406796200 · Cited by 606
Self-citationThe Proteasome of Mycobacterium tuberculosis Is Required for Resistance to Nitric Oxide
Darwin, K. H., Ehrt, S., Gutierrez-Ramos, J.-C., Weich, N., & Nathan, C. F. (2003) · Science · doi:10.1126/science.1091176 · Cited by 535
M. tuberculosis persistence, latency, and drug tolerance
Gomez, J. E., & McKinney, J. D. (2004) · Tuberculosis · doi:10.1016/j.tube.2003.08.003 · Cited by 533
Tuberculosis — metabolism and respiration in the absence of growth
Boshoff, H. I. M., & Barry, C. E. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1065 · Cited by 448
Self-citationRecent synthetic developments in the nitro to carbonyl conversion (Nef reaction)
Ballini, R., & Petrini, M. (2004) · Tetrahedron · doi:10.1016/j.tet.2003.11.016 · Cited by 438
Cited by
The spectrum of latent tuberculosis: rethinking the biology and intervention strategies
Barry, C. E., Boshoff, H. I., Dartois, V., Dick, T., Ehrt, S., Flynn, J., Schnappinger, D., Wilkinson, R. J., & Young, D. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2236 · Cited by 1,422
Self-citationTreatment of Highly Drug-Resistant Pulmonary Tuberculosis
Conradie, F., Diacon, A. H., Ngubane, N., Howell, P., Everitt, D., Crook, A. M., Mendel, C. M., Egizi, E., Moreira, J., Timm, J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1901814 · Cited by 1,044
The challenge of new drug discovery for tuberculosis
Koul, A., Arnoult, E., Lounis, N., Guillemont, J., & Andries, K. (2011) · Nature · doi:10.1038/nature09657 · Cited by 1,042
Advances in the development of new tuberculosis drugs and treatment regimens
Zumla, A., Nahid, P., & Cole, S. T. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4001 · Cited by 893
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., et al. (2009) · Science · doi:10.1126/science.1171583 · Cited by 740
Dheda, K., Gumbo, T., Maartens, G., Dooley, K. E., McNerney, R., Murray, M., Furin, J., Nardell, E. A., London, L., Lessem, E., et al. (2017) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(17)30079-6 · Cited by 684
Interferon-inducible effector mechanisms in cell-autonomous immunity
MacMicking, J. D. (2012) · Nature Reviews Immunology · doi:10.1038/nri3210 · Cited by 579
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
Conradie, F., Bagdasaryan, T. R., Borisov, S., Howell, P., Mikiashvili, L., Ngubane, N., Samoilova, A., Skornykova, S., Tudor, E., Variava, E., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119430 · Cited by 578
Almeida Da Silva, P. E., & Palomino, J. C. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr173 · Cited by 532
Anti-tuberculosis treatment strategies and drug development: challenges and priorities
Dartois, V. A., & Rubin, E. J. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00731-y · Cited by 490
Antibiotics in the clinical pipeline in 2013
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2013) · The Journal of Antibiotics · doi:10.1038/ja.2013.86 · Cited by 433
The path of anti-tuberculosis drugs: from blood to lesions to mycobacterial cells
Dartois, V. (2014) · Nature Reviews Microbiology · doi:10.1038/nrmicro3200 · Cited by 388
Formation, physiology, ecology, evolution and clinical importance of bacterial persisters
Van den Bergh, B., Fauvart, M., & Michiels, J. (2017) · FEMS Microbiology Reviews · doi:10.1093/femsre/fux001 · Cited by 381
Global tuberculosis drug development pipeline: the need and the reality
Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J., & Wang, X. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60359-9 · Cited by 374
Alvin, A., Miller, K. I., & Neilan, B. A. (2014) · Microbiological Research · doi:10.1016/j.micres.2013.12.009 · Cited by 373
Antibiotics in the clinical pipeline at the end of 2015
Butler, M. S., Blaskovich, M. A., & Cooper, M. A. (2017) · The Journal of Antibiotics · doi:10.1038/ja.2016.72 · Cited by 349
The Response of Mycobacterium Tuberculosis to Reactive Oxygen and Nitrogen Species
Voskuil, M. I., Bartek, I. L., Visconti, K., & Schoolnik, G. K. (2011) · Frontiers in Microbiology · doi:10.3389/fmicb.2011.00105 · Cited by 348
Dookie, N., Rambaran, S., Padayatchi, N., Mahomed, S., & Naidoo, K. (2018) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkx506 · Cited by 346
The Normalcy of Dormancy: Common Themes in Microbial Quiescence
Rittershaus, E. S. C., Baek, S.-H., & Sassetti, C. M. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.05.012 · Cited by 340
Christophe, T., Jackson, M., Jeon, H. K., Fenistein, D., Contreras-Dominguez, M., Kim, J., Genovesio, A., Carralot, J.-P., Ewann, F., Kim, E. H., et al. (2009) · PLoS Pathogens · doi:10.1371/journal.ppat.1000645 · Cited by 329
Self-citationMetabolic Regulation of Mycobacterial Growth and Antibiotic Sensitivity
Baek, S.-H., Li, A. H., & Sassetti, C. M. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001065 · Cited by 324
The mechanism of action of PA-824: Novel insights from transcriptional profiling
Manjunatha, U., Boshoff, H. I. M., & Barry, C. E. (2009) · Communicative & Integrative Biology · doi:10.4161/cib.2.3.7926 · Cited by 319
Self-citationMetabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis
Ehrt, S., Schnappinger, D., & Rhee, K. Y. (2018) · Nature Reviews Microbiology · doi:10.1038/s41579-018-0013-4 · Cited by 296
Antibiotics in the clinical pipeline in 2011
Butler, M. S., & Cooper, M. A. (2011) · The Journal of Antibiotics · doi:10.1038/ja.2011.44 · Cited by 272
Antibiotics in the clinical pipeline in October 2019
Butler, M. S., & Paterson, D. L. (2020) · The Journal of Antibiotics · doi:10.1038/s41429-020-0291-8 · Cited by 264
Wallis, R. S., Maeurer, M., Mwaba, P., Chakaya, J., Rustomjee, R., Migliori, G. B., Marais, B., Schito, M., Churchyard, G., Swaminathan, S., et al. (2016) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(16)00070-0 · Cited by 262
Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions
Harper, J., Skerry, C., Davis, S. L., Tasneen, R., Weir, M., Kramnik, I., Bishai, W. R., Pomper, M. G., Nuermberger, E. L., & Jain, S. K. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir786 · Cited by 256
Stanley, S. A., Grant, S. S., Kawate, T., Iwase, N., Shimizu, M., Wivagg, C., Silvis, M., Kazyanskaya, E., Aquadro, J., Golas, A., et al. (2012) · ACS Chemical Biology · doi:10.1021/cb300151m · Cited by 253
Self-citationFighting bacterial persistence: Current and emerging anti-persister strategies and therapeutics
Defraine, V., Fauvart, M., & Michiels, J. (2018) · Drug Resistance Updates · doi:10.1016/j.drup.2018.03.002 · Cited by 222
Jirapanjawat, T., Ney, B., Taylor, M. C., Warden, A. C., Afroze, S., Russell, R. J., Lee, B. M., Jackson, C. J., Oakeshott, J. G., Pandey, G., et al. (2016) · Applied and Environmental Microbiology · doi:10.1128/aem.02500-16 · Cited by 45
Adolph, C., McNeil, M. B., & Cook, G. M. (2022) · mBio · doi:10.1128/mbio.01672-22 · Cited by 32
Metadata
- Authors
- Singh, R., Manjunatha, U., Boshoff, H. I. M., Ha, Y. H., Niyomrattanakit, P., Ledwidge, R., Dowd, C. S., Lee, I. Y., Kim, P., Zhang, L., Kang, S., Keller, T. H., Jiricek, J., & Barry, C. E.
- Venue
- Science
- Published
- 2008-11-28
- Volume
- 322
- Issue
- 5906
- Pages
- 1392-1395
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2145085703
- Cited by
- 628
- References
- 19
- FWCI
- 21.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.